PhoenixBio Co (TSE:6190) Total Equity: 円1,553 Mil (As of Mar. 2026)


TSE:6190 PhoenixBio Co Ltd TSE:6190
55 GF Score
Price 円338.00
GF Value 円358.32
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is PhoenixBio Co Total Equity?

PhoenixBio Co TSE:6190 +0.30% 55 Total Equity is 円1,553 Mil as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 55/100 and a GF Value™ of 円358.32 (Fairly Valued). The stock has 5 warning signs investors should review.

PhoenixBio Co's total equity for the quarter that ended in Mar. 2026 was 円1,553 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

PhoenixBio Co Total Equity Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Total Equity Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 828.15 1,514.47 1,797.61 1,365.41 1,552.63

PhoenixBio Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,797.61 1,685.12 1,365.41 1,381.47 1,552.63
TSE:6190
55GF Score
PhoenixBio Co Ltd TSE:6190
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhoenixBio Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

PhoenixBio Co's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2192.682-640.055
=1,553

PhoenixBio Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2192.682-640.055
=1,553

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of 円1,553 Mil mean?
PhoenixBio Co (TSE:6190) has a Total Equity of 円1,553 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for PhoenixBio Co and its competitors.
Is PhoenixBio Co's Total Equity too high?
PhoenixBio Co's current Total Equity is 円1,553 Mil. Overall, PhoenixBio Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Total Equity compare to VRTX and REGN?
PhoenixBio Co's Total Equity of 円1,553 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for PhoenixBio Co and its competitors. PhoenixBio Co's current Total Equity is 円1,553 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円358.32, compared to a current price of 円338.00 — trading 5.7% below its estimated fair value. The current Total Equity is 円1,553 Mil. PhoenixBio Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Total Equity is 円1,553 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円338.00 is trading 5.7% below its estimated GF Value™ of 円358.32. GuruFocus considers PhoenixBio Co to be Fairly Valued.

Key valuation signals for TSE:6190:

  • Total Equity: 円1,553 Mil
  • GF Value™: 円358.32 vs. price of 円338.00 (5.7% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
55GF Score

Get the complete analysis for TSE:6190

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円338.00
Price
円358.32
GF Value